Using drugs to target necroptosis: dual roles in disease therapy

• Zhen Wang ^[1] ; Li-min Guo ^[1] ; Hong-kang Zhou ^[1] ; Hong-ke Qu ^[1] ; Shu-chao Wang ^[1] ; Feng-xia Liu ^[2] ; Dan Chen ^[1] ; Ju-fang Huang ^[1] ; Kun Xiong ^[1]
  1. [1] Central South University

     Central South University

     China

     
  2. [2] Xinjiang Medical University

     Xinjiang Medical University

     China

     
• Localización: Histology and histopathology: cellular and molecular biology, ISSN-e 1699-5848, ISSN 0213-3911, Vol. 33, Nº. 8, 2018, págs. 773-789
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Necroptosis is programmed necrosis, a process which has been studied for over a decade. The most common accepted mechanism is through the RIP1- RIP3-MLKL axis to regulate necroptotic cell death. As a result of previous studies on necroptosis, positive regulation for promoting necroptosis such as HSP90 stabilization and hyperactivation of TAK1 on RIP1 is clear. Similarly, the negative regulation of necroptosis, such as through caspase 8, c-FLIP, CHIP, MK2, PELI1, ABIN-1, is also clear. Therefore, the promise of corresponding applications in treating diseases becomes hopeful. Studies have shown that necroptosis is involved in the development of many diseases, such as ischemic injury diseases in various organs, neurodegenerative diseases, infectious diseases, and cancer. Given these results, drugs that inhibit or trigger necroptosis can be discovered to treat diseases. In this review, we briefly introduce up to date concepts concerning the mechanism of necroptosis, the diseases that involve necroptosis, and the drugs that can be applied to treat such diseases.